title: From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials.
authors.affiliation: Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA. jiil_heemskerk@ninds.nih.gov
authors.forename: Jill
authors.initials: J
authors.lastname: Heemskerk
authors.forename: Allan J
authors.initials: AJ
authors.lastname: Tobin
authors.forename: Bernard
authors.initials: B
authors.lastname: Ravina
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000941:ethics / Q000639:trends*; D004195:Disease Models, Animal; D015195:Drug Design; D004341:Drug Evaluation / Q000941:ethics / Q000639:trends*; D004353:Drug Evaluation, Preclinical / Q000941:ethics / Q000639:trends*; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D011237:Predictive Value of Tests; D018570:Risk Assessment / Q000941:ethics / Q000592:standards